In today’s briefing:
- Intuitive Surgical: What Are Its Latest Advancements in Robotic-Assisted Surgery Technology & Key Growth Levers?
- China Healthcare Weekly (Jul.27)-The Turning Point of Tigermed and CRO, Everest Medicines’ Placement
- IQVIA Holdings Inc.: AI & Technology Implementation to Position IQVIA At The Forefront Of Innovation In Life Sciences & Healthcare!
- Medpace Is Expanding Decentralized Clinical Trials & Improving Global Trial Capabilities But Is It ENOUGH?
- Quest Diagnostics: Capitalizing On Advanced Diagnostics & Utilization Trends & Other Major Growth Drivers!
Intuitive Surgical: What Are Its Latest Advancements in Robotic-Assisted Surgery Technology & Key Growth Levers?
- Intuitive Surgical’s recent quarterly results highlight a strong performance, marked by a 21% increase in revenues and a pro forma earnings per share rise of 23%.
- The company saw robust growth in procedure volumes, with da Vinci procedures increasing by 17%, attributed to strong performance in benign general surgery in the U.S. and a notable rise in international procedures outside urology.
- The introduction of their latest robotic platform, the da Vinci 5, is beginning to show positive traction with broad launches underway in the U.S., and initial adoption in Europe and Japan following regulatory clearances.
China Healthcare Weekly (Jul.27)-The Turning Point of Tigermed and CRO, Everest Medicines’ Placement
- The drug list of 11th national VBP varieties has been released. Innovative drugs will not be included in VBP. Results of this VBP is expected to be implemented by 2025.
- The performance improvement of CRO may not be reflected until 25Q3 or 25Q4 at the earliest, but the market may reflect this expectation in advance. Tigermed’s turning point is coming.
- Everest Medicines’ Placing Price is expensive.The reduction of holdings by major shareholder CBC and Founder Fu Wei indicates that the Company has been overvalued. Valuation should be lower than BeiGene.
IQVIA Holdings Inc.: AI & Technology Implementation to Position IQVIA At The Forefront Of Innovation In Life Sciences & Healthcare!
- IQVIA marked a significant milestone in the second quarter of 2025 by surpassing $4 billion in quarterly revenue, a first in the company’s history.
- This revenue achievement was noted to be above the high end of the anticipated guidance.
- Adjusted EBITDA and adjusted diluted EPS also performed well, aligning with or eclipsing the expected targets.
Medpace Is Expanding Decentralized Clinical Trials & Improving Global Trial Capabilities But Is It ENOUGH?
- Medpace Holdings, Inc. recently reported its second-quarter 2025 earnings, revealing both strengths and challenges.
- Revenue for the quarter was $603.3 million, marking a 14.2% increase year-over-year.
- The uptick was driven by higher reimbursable activities, particularly in therapeutic areas like metabolic studies where costs are higher than average, alongside a shift in therapeutic focus away from oncology.
Quest Diagnostics: Capitalizing On Advanced Diagnostics & Utilization Trends & Other Major Growth Drivers!
- Quest Diagnostics, a prominent player in the medical diagnostics sector, presented its second-quarter 2025 results, highlighting a blend of strategic growth and operational challenges.
- The company’s performance was marked by a notable 15.2% increase in consolidated revenues to $2.76 billion compared to the previous year, driven by organic growth and strategic acquisitions.
- This growth was primarily fueled by heightened demand for advanced diagnostic solutions and expanded relationships with enterprise accounts.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
